10X Genomics Inc. has been valued at more than $1 billion, but a far less heralded start-up has some advice to help the Silicon Valley unicorn with a $24 million patent problem.
Less-than-a-year-old Ex Parte uses court data and a proprietary ranking system based on real-life lawyers’ experience and past results to predict who will win appeals in patent cases at the Federal Circuit.
That court is where 10X Genomics is likely headed after a Delaware jury said the biotech company owed a competitor $24 million for patent infringement and a judge ruled the company will have to stop selling ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.